Whitepapers eBooks and Webinars on Discovery Management from James Samanen Consulting

We offer the following Whitepapers, eBooks and Webinars on Discovery Management.

  1. Managing Risk and Value in Biopharmaceutical R&D – whitepaper, webinar
  2. Small Molecule, Peptide and Protein-Based Drugs – The Differences and Similarities – eBook and webinar
  3. The Differences between Discovery & Development Project and Portfolio Management Come Down to the Level of Risk – whitepaper, webinar

Scroll down to learn more about each of these offerings.


1. Managing Risk and Value in Biopharmaceutical R&D – whitepaper, webinar

In this downloadable PDF file, we describe a methodology that is similar to a system that was used in a major pharmaceutical company to measure risk in the Target Discovery phase for many years. We believe that the full value of this system could be exploited through all phases of drug discovery and even the entire R&D pipeline.

We have organized the discussion into the following topics.
1. Risk is Related to the Probability of Failure, the Inverse of POS
2. Defining and Managing Risk in Drug Discovery
3. Managing Risk in Drug Discovery via Target Validation POS and Target Tractability POS
4. Defining and Managing Risk in Drug Development
5. Estimating Value in Drug Discovery, p. 12 6. Estimating Value in Drug Development

This whitepaper may be purchased for $100, via Paypal. Please Contact Us and we will send you a Paypal invoice. Upon receipt of payment we will email you the PDF file.

This content can also be delivered as a webinar upon arrangement with James Samanen Consulting.


2. Small Molecule, Peptide and Protein-Based Drugs – The Differences and Similarities – eBook and webinar

In our downloadable eBook, available in PDF format, we endeavor to shed light on both the differences and similarities in the discovery and development of small molecules and biologics. The paper is packed with references gleaned from our review of the literature. It covers the recent study by Trusheim et al. (Forum for Health Economics & Policy, 2010 13, issue 1, article 4) and includes highlights from the recent analysis of drug approvals sponsored by the Biotechnology Industry Organization. (BIO CEO & Investor Conference, February 15th, 2011BIO)

We have organized the discussion into the following topics.

  1. Introduction
  2. Size
  3. Peptide Drugs Fill the Gap Between Small Molecules and Biomolecules
  4. Structure
  5. Synthesis
  6. Differences in Terminology
  7. The Progression of Technologies that Fueled the Development of Small Molecule, Peptide and Protein-Based Drugs
    7.1 Important Learnings from Small Molecule Drug Discovery
    7.2The Rapid Ascendency of Protein-Based Drugs
    7.2.1 Important Learnings Analogous to Small Molecules
    7.2.2 Which was more important in the early days – the Biotech company or the Pharmaceutical Company?
    7.2.3 The Classes of Protein-Based Drugs
    7.3 Peptides – Ready to Boom?
  8. Comparing Drug Properties
    8.1 Expanding the Druggable Genome with Peptide and Protein-Based Drugs
  9. Comparing Success Rates, Cycle Times and Costs
  10. Comparing CMC – Chemical Manufacture and Control
  11. Comparing Pricing Strategies
  12. Glycoprotein IIB/IIIA Antagonists, a Case Study
    12.1 Three Commmecially Available Antagonists
    12.2 Rational Design of Oral Nonpeptide Mimetics from Peptides
    12.3 The Search for Small Molecule Protein-Protein Inhibitors
  13. Insulin – the Teacher
  14. Biosimilars and Biobetters versus Generics
  15. Differences in Discovery and Preclinical Stages
  16. Diminishing Differences in Therapy Areas
  17. Small Molecule, Peptide and Biomolecular Management by Division versus Platform

This eBook may be purchased for $150, via Paypal. Please Contact Us and we will send you a Paypal invoice. Upon receipt of payment we will email you the PDF file.

This content can also be delivered as a webinar upon arrangement with James Samanen Consulting.


3. The Differences between Discovery & Development Project and Portfolio Management Come Down to the Level of Risk – whitepaper, webinar

Did you ever wonder why project and portfolio management in Bio/pharmaceutical Discovery is so different from Bio/pharmaceutical Development? There are very good reasons for those differences and these stem from the different levels of risk inherent in projects in Discovery versus projects in Development. In this paper available as a downloadable PDF file we examine how this all comes about and then consider the ramifications. We will see why the solution to a project or portfolio management problem in Discovery could be different from a solution to the same project or portfolio management problem in Development.

This whitepaper may be purchased for $100, via Paypal. Please Contact Us and we will send you a Paypal invoice. Upon receipt of payment we will email you the PDF file.

This content can also be delivered as a webinar upon arrangement with James Samanen Consulting.